ICLR241220P330000
- 0.00
- 0.000.00%
Icon PLC Newsroom
Are Investors Undervaluing ICON Public Limited Company (NASDAQ:ICLR) By 48%?
Trump Taps Jay Bhattacharya to Lead National Institutes of Health
Baird Upgrades Icon PLC(ICLR.US) to Buy Rating, Raises Target Price to $242
Icon PLC (ICLR) Down 4.1% Since Last Earnings Report: Can It Rebound?
Should You Retain Your Conviction in Icon Plc (ICLR)?
Icon Is Maintained at Neutral by Baird
Icon Price Target Cut to $225.00/Share From $249.00 by Baird
Baird Downgrades Icon PLC(ICLR.US) to Hold Rating, Cuts Target Price to $225
Express News | ICON PLC : Leerink Partners Cuts Target Price to $255 From $270
Pharmacovigilance and Drug Safety Software Market Skyrockets to $359.30 Million by 2031 Dominated by Tech Giants - ArisEurope, ICON Plc and Syneos Health | The Insight Partners
Express News | Shares of IQVIA, Charles River and ICON PLC Down Between 2% and 3%
Express News | Shares of Contract Drug Researchers Fall After Rfk Jr Picked for Top US Health Agency Role
Elliott Investment Management Adds To Southwest, Western Digital, Etsy, Match Group; Trims BILL Holdings, Seadrill, BlackLine, NRG Energy In Q3
Should You Think About Buying ICON Public Limited Company (NASDAQ:ICLR) Now?
ICON Plc to Present at the Jefferies London Healthcare Conference
ICON (NASDAQ:ICLR) Sheds 3.0% This Week, as Yearly Returns Fall More in Line With Earnings Growth
Express News | Icon Shares Are Trading Higher. Truist Securities Maintained a Buy Rating on the Stock
$1000 Invested In This Stock 15 Years Ago Would Be Worth $9,100 Today
Icon Price Target Cut to $295.00/Share From $363.00 by Truist Securities
Icon Is Maintained at Buy by Truist Securities